Drug Profile
Elexacaftor/ivacaftor/tezacaftor + ivacaftor - Vertex Pharmaceuticals
Alternative Names: Elexacaftor/ivacaftor/tezacaftor - Vertex Pharmaceuticals; ELX/TEZ/IVA; Ivacaftor/tezacaftor/VX 445; Kaftrio; Tezacaftor/VX-445/ivacaftor; TRIKAFTA; TRIKAFTA®; VX 445/ivacaftor/tezacaftor; VX-445/TEZ/IVA; VX-445/VX-661/VX-770Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
- Developer Vertex Pharmaceuticals
- Class Amides; Aminophenols; Antifibrotics; Benzodioxoles; Cyclopropanes; Fluorinated hydrocarbons; Fluorobenzenes; Indoles; Pyrazoles; Pyridines; Pyrrolidines; Quinolones; Small molecules; Sulfonamides
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cystic fibrosis
Most Recent Events
- 24 Feb 2024 Vertex Pharmaceuticals completes a phase III trial for Cystic fibrosis (In adolescents, In adults, In children, In the elderly) in USA, Australia, Canada, Ireland, and United Kingdom (PO, Tablet) (NCT04183790) (EudraCT2019-001827-11)
- 05 Feb 2024 The European Commission approves label extension of KAFTRIO in combination with ivacaftor in children with cystic fibrosis 2 to 5 years of age who have at least one F508del mutation in the CFTR gene
- 05 Feb 2024 The European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) extension for KAFTRIO in combination with ivacaftor to include people with CF 2 years of age with N1303K mutation